Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Yumanity Therapeutics Q2 EPS $(1.03)

Yumanity Therapeutics (NASDAQ:YMTX) reported quarterly losses of $(1.03) per share.

byMichael Horton

August 12, 2021

1 minute read

Yumanity Therapeutics (NASDAQ:YMTX) reported quarterly losses of $(1.03) per share.

HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target

By Benzinga Newsdesk

February 24, 1:56 PM

HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $20 price target.

ATXS

William Blair Initiates Coverage On Amplitude with Outperform Rating

By Benzinga Newsdesk

October 25, 8:12 AM

William Blair analyst Bhavan Suri initiates coverage on Amplitude (NASDAQ:AMPL) with a Outperform rating.

AMPL

Velodyne Lidar Q2 Adj. EPS $(0.18) Misses $(0.14) Estimate, Sales $13.60M Miss $17.18M Estimate

By Benzinga Newsdesk

August 5, 4:07 PM

Velodyne Lidar (NASDAQ:VLDR) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. The company reported quarterly sales of $13.60 million which missed

VLDR

Barclays Downgrades Avis Budget Gr to Underweight, Raises Price Target to $217

By Benzinga Newsdesk

November 16, 7:09 AM

Barclays analyst Brian Johnson downgrades Avis Budget Gr (NASDAQ:CAR) from Equal-Weight to Underweight and raises the price target from $125 to $217.

CAR

Yumanity Therapeutics Q2 EPS $(1.03)

Related Posts

HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target

William Blair Initiates Coverage On Amplitude with Outperform Rating

Velodyne Lidar Q2 Adj. EPS $(0.18) Misses $(0.14) Estimate, Sales $13.60M Miss $17.18M Estimate

Barclays Downgrades Avis Budget Gr to Underweight, Raises Price Target to $217